Seelos Therapeutics Inc (NASDAQ:SEEL) announced Monday that it has scheduled a meeting with federal regulators as it advances its SLS-002 intranasal racemic ketamine depression drug.
In a statement, the company said in March, it will seek guidance from the US Food and Drug Administration (FDA) for an adaptive Phase III trial of SLS-002 for Acute Suicidal Ideation and Behavior (ASIB) in patients with Major Depressive Disorder (MDD).
“Continued communication with FDA is essential for the development of SLS-002 in this high unmet need of ASIB in MDD,” said CEO Raj Mehra.
READ: Seelos starts dosing in Phase I study of SLS-002 intranasal ketamine depression drug
“We are diligently striving to advance the program forward as we share the Phase I data from the ongoing studies throughout the first quarter,” he added.
Seelos, based in New York, recently received Fast Track designation for SLS-002 for the treatment of ASIB in patients with MDD.
Data from the ongoing Phase I studies of SLS-002 to evaluate the pharmacokinetics, pharmacodynamics, and drug-drug interactions are expected throughout the first quarter of 2020.
Seelos' stock recently traded 7.5% higher to $1.43 a share in New York.
--ADDS stock price--
Contact the author: patrick@proactiveinvestors.com
Follow him on Twitter @PatrickMGraham